^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ROS1 wild-type

    i
    Other names: ROS1, ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, V-Ros Avian UR2 Sarcoma Virus Oncogene Homolog 1, C-Ros Oncogene 1 Receptor Tyrosine Kinase, Proto-Oncogene Tyrosine-Protein Kinase ROS, Proto-Oncogene C-Ros-1, MCF3, ROS, V-Ros UR2 Sarcoma Virus Oncogene Homolog 1 (Avian), ROS Proto-Oncogene 1 Receptor Tyrosine Kinase, Transmembrane Tyrosine-Specific Protein Kinase, Receptor Tyrosine Kinase C-Ros Oncogene 1, C-Ros Receptor Tyrosine Kinase, Proto-oncogene C-Ros, C-Ros-1
    Entrez ID:
    6098
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    5d
    A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade in Patients With Locally Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=56, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting | Trial completion date: Sep 2029 --> Dec 2029 | Initiation date: Sep 2025 --> Jan 2026 | Trial primary completion date: Sep 2029 --> Dec 2029
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date • Checkpoint inhibition
    |
    EGFR (Epidermal growth factor receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 wild-type
    |
    Avastin (bevacizumab) • cisplatin • albumin-bound paclitaxel
    3ms
    In silico design of natural-based structures as drug candidates to inhibit ROS1 protein. (PubMed, Sci Rep)
    In addition, LIG48 and crizotinib remained within the mutated and wild-type ROS1 kinase domains in all replicas, for a total simulation time of 400 ns for each system. This research presents a promising and potentially effective route for designing kinase inhibitors that could address resistance and side effects associated with existing therapies.
    Journal
    |
    ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 wild-type
    |
    Xalkori (crizotinib)
    3ms
    Combination Therapy with Hypofractionated Radiotherapy, GM-CSF, and Benmelstobart Followed by Bemzutizumab Plus Anlotinib Maintenance in Driver Mutation-Negative Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Who Failed Prior PD-1/PD-L1 Inhibitor Therapy: A Single-Arm Exploratory Study (ChiCTR2500108817)
    P2, N=69, Not yet recruiting, The Second Affiliated Hospital of Nanjing Medical University; The Second Affiliated Hospital of Nanjing Medical University
    New P2 trial • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • ALK wild-type • ROS1 wild-type • EGFR negative
    |
    Focus V (anlotinib) • Andewei (benmelstobart)
    3ms
    Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, Georgetown University | Recruiting --> Active, not recruiting | N=42 --> 29
    Enrollment closed • Enrollment change
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ALK wild-type • ROS1 wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)
    5ms
    ROS1 mutations promote an immunosuppressive tumor microenvironment via MYC to confer immune evasion in head and neck cancer. (PubMed, Cancer Drug Resist)
    ROS1 mutations drive ICI resistance in HNC by promoting an immunosuppressive TME via MYC-mediated transcriptional reprogramming, impairing antigen presentation and T cell function. Incorporating ROS1 status into biomarker panels may improve patient stratification and guide combinatorial therapies targeting both immune evasion and oncogenic pathways.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL9 (Chemokine (C-X-C motif) ligand 9)
    |
    TMB-H • ROS1 wild-type
    6ms
    SBRT followed by neoadjuvant iparomlimab and tuvonralimab plus adjuvant iparomlimab and tuvonralimab for resectable stage IIB-IIIB NSCLC: a single-arm, phase II study (ChiCTR2500105709)
    P2, N=39, Recruiting, Cancer Hospital Affiliated of Shandong First Medical University; Cancer Hospital Affiliated of S handong First Medical Univer sity
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ROS1 wild-type
    |
    Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    8ms
    Lung Immune Prognostic Index-Based Predictive Score in Advanced Non-Small Cell Lung Cancer with a Programmed Death Ligand-1 Tumor Proportion Score ≥ 50. (PubMed, J Clin Med)
    We assessed whether LIPI, in combination with baseline clinical characteristics, can guide first-line treatment selection between pembrolizumab (P) and pembrolizumab plus platinum-based chemotherapy (PCT) in patients with PD-L1 tumor proportion score (TPS) ≥ 50% and EGFR/ALK/ROS1 wild-type... This LIPI-based predictive score may assist in identifying aNSCLC patients who derive greater benefit from chemo-immunotherapy over immunotherapy. Its simplicity and clinical relevance support integration into treatment decision-making, pending prospective validation.
    Journal • Tumor proportion score • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK wild-type • ROS1 wild-type
    |
    Keytruda (pembrolizumab)
    8ms
    Anlotinib Plus Docetaxel is Promising in Advanced NSCLC Progressing on First-Line Immunotherapy: A Pooled Analysis of Two Randomized Trials. (PubMed, Adv Ther)
    Anlotinib plus docetaxel improved PFS but not OS versus docetaxel in patients with advanced NSCLC progressing on ICIs. Larger standardized phase 3 trials are needed to verify these findings.
    Retrospective data • Journal
    |
    EGFR (Epidermal growth factor receptor) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK wild-type • ROS1 wild-type
    |
    docetaxel • Focus V (anlotinib)
    12ms
    Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC (clinicaltrials.gov)
    P2, N=42, Recruiting, Georgetown University | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ALK wild-type • ROS1 wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)
    over1year
    Study to Evaluate the Safety and Anti-tumor Activity of SCC244 (clinicaltrials.gov)
    P1, N=56, Completed, Haihe Biopharma Co., Ltd. | Unknown status --> Completed | N=113 --> 56
    Trial completion • Enrollment change • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR mutation • MET amplification • MET exon 14 mutation • MET overexpression • ALK mutation • MET mutation • ROS1 wild-type
    |
    Haiyitan (gumarontinib)
    over1year
    Induction Chemo-Nivo in Unresectable Stage III NSCLC (clinicaltrials.gov)
    P2, N=1, Terminated, Ralph G Zinner | N=37 --> 1 | Trial completion date: Aug 2027 --> Jul 2024 | Recruiting --> Terminated | Trial primary completion date: Jun 2025 --> Jul 2024; Slow accrual
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Surgery
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK wild-type • ROS1 wild-type
    |
    Opdivo (nivolumab) • paclitaxel • docetaxel
    over1year
    Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC (clinicaltrials.gov)
    P2, N=42, Recruiting, Georgetown University | Trial completion date: Jul 2024 --> Dec 2024 | Trial primary completion date: Jul 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • ALK wild-type • ROS1 wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • tiragolumab (RG6058)